Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Secondary Myelofibrosis: early-phase trial registry
4 of 13 indexed Secondary Myelofibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 4 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Secondary Myelofibrosis: 13 US clinical trials tracked, 4 recruiting.
Secondary Myelofibrosis is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition secondary-myelofibrosis
OPEN 4 | RECR 31% | LATE 0 | EARLY 13 | RANK #1315 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Decompensated Heart Failure (31% recruiting · 13 trials)
Secondary Myelofibrosis lists 4 open slots (31% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Secondary Myelofibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Secondary Myelofibrosis is recruiting below its size-band peers.
4 of 13 indexed trials (30.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Secondary Myelofibrosis research.
Fred Hutchinson Cancer Center accounts for 4 of 13 trials (30.8%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Secondary Myelofibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 13 trials that report a genuine target (sentinel values excluded). 13 of those (100%) plan for fewer than 100 participants.
-
Secondary Myelofibrosis research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
NCT06661915
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
NCT07228624
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
NCT04282187
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
Fred Hutchinson Cancer Center
NCT04370301
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Fred Hutchinson Cancer Center
NCT02251821
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
City of Hope Medical Center
NCT04339101
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
Fred Hutchinson Cancer Center
NCT04384692
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis
City of Hope Medical Center
NCT03118492
Decitabine in Treating Patients With Myelofibrosis
National Cancer Institute (NCI)
NCT00095784
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT05364762
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Geron Corporation
NCT01731951
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
M.D. Anderson Cancer Center
NCT03426969
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on Secondary Myelofibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Secondary Myelofibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Secondary Myelofibrosis page
13 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Secondary Myelofibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Secondary Myelofibrosis trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Secondary Myelofibrosis condition card totals 13 registered trials; most-linked intervention Cyclophosphamide; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.